Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$108.53 USD

108.53
2,050,572

-2.54 (-2.29%)

Updated May 20, 2024 04:00 PM ET

After-Market: $109.00 +0.47 (0.43%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ILMN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Illumina, Inc. [ILMN]

Reports for Purchase

Showing records 261 - 280 ( 361 total )

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 261

02/02/2015

Industry Report

Pages: 5

Canadian Healthcare - Biotechnology Weekly Update

Provider: Clarus Securities

Analyst: NOVAK D

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 262

01/28/2015

Company Report

Pages: 12

Higher Quality 4Q14 Results - Entire System Portfolio Outperforms - FCF Improving - Several Ways to Win in 2015 - Upping PT to $230 - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 263

01/23/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 26

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 264

01/21/2015

Company Report

Pages: 9

President''s Precision Med Initiative Light on Details - Expecting In-line 4Q14 Results Post Preannouncement - Gov''t Orders Ok - Maintain OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 265

01/20/2015

Company Report

Pages: 9

Expecting Ok 4Q14 Results - Dx Theme In Focus - Potential NIH Program Helps Calm 2015 Growth Fears - Gov''t Tracker In-line - Maintain OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 266

12/09/2014

Company Report

Pages: 8

Price: 24.95

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 267

11/26/2014

Daily Note

Pages: 9

NIPT Update - Confusing Study/Letter Creates a Slight Near-Term Distraction

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 268

11/26/2014

Daily Note

Pages: 9

NIPT Update - Confusing Study/Letter Creates a Slight Near-Term Distraction - NIPT Strategy - MO Likely Unaffected - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 269

10/31/2014

Company Report

Pages: 13

Banner 3Q14 Results - System Demand Drives Beat Again - Utilization Ok & NIPT Sales Inflect Nicely - Guidance Upped - Reiterating OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 50.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 270

10/21/2014

Company Report

Pages: 13

Banner 3Q14 Results - System Demand Drives Beat Again - Utilization Ok & NIPT Sales Inflect Nicely - Guidance Upped - Reiterating OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 50.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 271

10/13/2014

Company Report

Pages: 8

Expecting Robust 3Q14 Results - Continue to Hear of Quiet Pre-Natal Licensing Deals

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 272

09/16/2014

Industry Report

Pages: 4

Medical Diagnostics and Life Sciences Tools - Ariosa Publishes New NIPT Approach

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 273

09/16/2014

Company Report

Pages: 8

Price: 24.95

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 274

09/10/2014

Company Report

Pages: 8

Pre-Natal & Gov''t Update - Deep Discussion with New US NIPT Player - Ariosa Sends Letter to LabCorp Customers - VA Activity Intriguing - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 275

07/24/2014

Company Report

Pages: 13

Strong 2Q14 Beat Driven By X Ten & NextSeq Placements - System Utilization Not As Strong - Good GM and FCF Progress - Raising PT to $165 - Maintain N

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 50.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 276

07/18/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE-The Week Ahead in Life Sciences - Upcoming Events for the Week of July 21

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 277

07/15/2014

Company Report

Pages: 9

Gov''t Demand Tracker Indicates Positively - Tweaking Street-High Estimates Slightly Lower - 2Q14 Beat Setup Still Looks Solid

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 278

06/30/2014

Daily Note

Pages: 10

Checks Suggest ILMN Has Won an Exclusive Competitive Contract with Progenity

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 279

06/30/2014

Daily Note

Pages: 10

Checks Suggest ILMN Has Won an Exclusive Competitive Contract with Progenity

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 280

06/24/2014

Company Report

Pages: 8

Price: 24.95